Carvedilol improved diabetic rat cardiac function depending on antioxidant ability.

Area of Science:

• Cardiovascular Disease Research
• Diabetology
• Pharmacology

Background:

• Diabetes mellitus significantly elevates cardiovascular disease risk, with oxidative stress as a key pathogenic factor.
• The Bcl-2 gene plays a role in combating oxidative stress, and carvedilol exhibits antioxidant properties.

Purpose of the Study:

• To investigate the effects of carvedilol on antioxidant status and Bcl-2 gene expression in healthy and diabetic rat hearts.
• To assess carvedilol's impact on cardiac function in a model of diabetes-induced cardiovascular dysfunction.

Main Methods:

• Healthy and streptozotocin-induced diabetic rats were administered low or high doses of carvedilol (1 or 10mg/kg/d) for 5 weeks.
• Hemodynamic parameters, malondialdehyde (MDA) levels, superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px) activities were measured.
• Cardiac Bcl-2 mRNA expression was analyzed in all experimental groups.

Main Results:

• Carvedilol administration improved hemodynamic parameters (LVEDP, +/-dP/dtmax) in diabetic rats.
• Diabetic rats exhibited increased MDA and CAT activity, with decreased SOD and GSH-Px activity, which were normalized by carvedilol.
• Carvedilol treatment upregulated antioxidant enzyme activities and Bcl-2 expression in both healthy and diabetic rat hearts.

Conclusions:

• Carvedilol demonstrates significant cardioprotective effects in diabetic rats, primarily through its potent antioxidant properties.
• The drug enhances cardiac antioxidant defense mechanisms and promotes the expression of the protective Bcl-2 gene.
• Carvedilol's ability to scavenge free radicals and improve cardiac function highlights its therapeutic potential in diabetic cardiomyopathy.